Skip to main content

Table 3 Association of Polymorphisms cMyc-N11S and p27-V109G with Tumor Characteristics (N = 967)

From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis

  T Stage1 Nodal Involvement Grade Estrogen Receptor2
  Low (N = 607) High (N = 315) None (N = 538) >= 1 (N = 356) I (N = 196) II&III (N = 710) Negative (N = 279) Positive (N = 659)
cMyc-N11S (A>G)         
AA 553(92.6%) 279(89.7%) 490(91.9%) 315(91.0%) 174(90.2%) 642(92.2%) 249(90.2%) 600(92.6%)
AG/GG 44 (7.4%) 32 (10.3%) 43 (8.1%) 31 (9.0%) 19 (9.8%) 54 (7.8%) 27 (9.8%) 48 (7.4%)
p-value 0.13   0.64   0.35   0.23  
p27-V109G (T>G)         
TT 371(62.8%) 177(56.9%) 334(63.1%) 197(57.4%) 116(60.7%) 423(61.1%) 166(59.9%) 399(62.3%)
TG 198(33.5%) 109(35.1%) 174(32.9%) 122(35.6%) 66 (34.6%) 234(33.8%) 99 (35.7%) 206(32.2%)
GG 22 (3.7%) 25 (8.0%) 21 (4.0%) 24 (7.0%) 9 (4.7%) 35 (5.1%) 12 (4.3%) 35 (5.5%)
p-value 0.01   0.07   0.97   0.50  
  1. 1 Low (pT1-2 or < 2 cm) and High (pT3-pT4 or > 2 cm), pTx excluded; 2 equivocal results grouped with positives.